Cat. No.: HY-17401

Ranolazine dihydrochloride

(Synonyms: CVT 303 dihydrochloride; RS 43285)

5 Cited Publications

Customer Review

Based on 5 publication(s) in Google Scholar

Ranolazine dihydrochloride (CVT 303 dihydrochloride) is an anti-angina agent that achieves its effects by inhibiting the late phase of inward sodium current (I_Na and I_Kr with IC₅₀ values of 6 μM and 12 μM, respectively) without affecting heart rate or blood pressure (BP). Ranolazine dihydrochloride is also a partial fatty acid oxidation inhibitor.

For research use only. We do not sell to patients.

Purity: 99.99%
CAS No.: 95635-56-6
Formula: C₂₄H₃₅Cl₂N₃O₄
Molecular Weight:500.46

Storage:

4°C, sealed storage, away from moisture

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Ranolazine dihydrochloride Chemical Structure

CAS No.: 95635-56-6

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- IC₅₀ & Target
- In Vivo
Chemical Information
Publications (5)
Solvent & Solubility
- In Vitro
- In Vivo
Purity & Documentation
References
Help & FAQs
Classifications
Bioz

Biological Activity

Description

Ranolazine dihydrochloride (CVT 303 dihydrochloride) is an anti-angina agent that achieves its effects by inhibiting the late phase of inward sodium current (I_Na and I_Kr with IC₅₀ values of 6 μM and 12 μM, respectively) without affecting heart rate or blood pressure (BP)^[1]^[2]. Ranolazine dihydrochloride is also a partial fatty acid oxidation inhibitor^[3].

IC₅₀ & Target

IC50: 6 μM (I_Na), 12 μM (I_Kr)^[1]

All Calcium Channel Isoforms :

All Sodium Channel Isoforms :

In Vivo

Ranolazine (Bolus injection 10 mg/kg and infusion 9.6 mg/kg/h; bolus injection; for 145 minutes; male Wistar rats) treatment significantly reduces infarct size and cardiac troponin T release in rats subjected to left anterior descending coronary artery occlusion-reperfusion^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Male Wistar rats (240-350 g)^[3]
Dosage:

Bolus injection 10 mg/kg and infusion (9.6 mg/kg/h)
Administration:

Bolus injection; for 145 minutes
Result:

Significantly reduced infarct size and cardiac troponin T release in rats subjected to left anterior descending coronary artery occlusion-reperfusion.

Chemical Information

CAS No. 95635-56-6
Appearance Solid
Molecular Weight 500.46
Formula C₂₄H₃₅Cl₂N₃O₄
Color White to off-white
SMILES

O=C(NC1=C(C)C=CC=C1C)CN2CCN(CC(O)COC3=CC=CC=C3OC)CC2.[H]Cl.[H]Cl
Synonyms

CVT 303 dihydrochloride; RS 43285
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

4°C, sealed storage, away from moisture

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Publications (5)

All WB

Sort by:

Journal Impact Factor

Cancer Res

KRAS Signaling Inhibition Induces a Targetable Metabolic Dependency on Lipophagy-Dependent Fatty Acid Oxidation in Pancreatic Cancer. [Abstract]

2026 Apr 29:10.1158/0008-5472.CAN-24-1984. PMID: 42054558
Theranostics

Adipocytes fuel gastric cancer omental metastasis via PITPNC1-mediated fatty acid metabolic reprogramming. [Abstract]

2018 Oct 29;8(19):5452-5468. PMID: 30555557

Ranolazine dihydrochloride purchased from MedChemExpress. Usage Cited in: Theranostics. 2018 Oct 29;8(19):5452-5468. [Abstract]

Western Blot analysis of vector or PITPNC1 overexpressing BGC823 and AGS which are seeded and treated with Ranolazine.
J Invest Dermatol

The regulators of peroxisomal acyl-carnitine shuttle CROT and CRAT promote metastasis in melanoma. [Abstract]

2023 Feb;143(2):305-316.e5. PMID: 36058299
Pharmaceutics

Drug-Induced Reorganisation of Lipid Metabolism Limits the Therapeutic Efficacy of Ponatinib in Glioma Stem Cells. [Abstract]

2024 May 29;16(6):728. PMID: 38931850
Philos Trans R Soc Lond B Biol Sci

Late sodium current in synergism with Ca2+/calmodulin-dependent protein kinase II contributes to β-adrenergic activation-induced atrial fibrillation. [Abstract]

2023 Jun 19;378(1879):20220163. PMID: 37122215

Solvent & Solubility

In Vitro:

DMSO : ≥ 50 mg/mL (99.91 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

H₂O : ≥ 50 mg/mL (99.91 mM)

* "≥" means soluble, but saturation unknown.

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

1.9982 mL

9.9908 mL

19.9816 mL

5 mM

0.3996 mL

1.9982 mL

3.9963 mL

10 mM

0.1998 mL

0.9991 mL

1.9982 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Working Solution

For the following dissolution methods, please prepare the working solution directly:

It is recommended to prepare fresh solutions and use them promptly within a short period of time.

The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: PBS

Solubility: 100 mg/mL (199.82 mM); Clear solution; Need ultrasonic

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (275 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Keating GM. Ranolazine: A Review of Its Use as Add-On Therapy in Patients with Chronic Stable Angina Pectoris. Drugs. 2013 Jan;73(1):55-73. [Content Brief]

[2]. Wang WQ, Robertson C, Dhalla AK, Belardinelli L. Antitorsadogenic effects of ({+/-})-N-(2,6-dimethyl-phenyl)-(4[2-hydroxy-3-(2-methoxyphenoxy)propyl]-1-piperazine (ranolazine) in anesthetized rabbits. J Pharmacol Exp Ther. 2008 Jun;325(3):875-81. doi: 10.1124/jpet.108.137729. Epub 2008 Mar 5. [Content Brief]

[3]. Zacharowski K, Blackburn B, Thiemermann C. Ranolazine, a partial fatty acid oxidation inhibitor, reduces myocardial infarct size and cardiac troponin T release in the rat. Eur J Pharmacol. 2001 Apr 20;418(1-2):105-10. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO / H₂O	1 mM	1.9982 mL	9.9908 mL	19.9816 mL	49.9540 mL
	5 mM	0.3996 mL	1.9982 mL	3.9963 mL	9.9908 mL
	10 mM	0.1998 mL	0.9991 mL	1.9982 mL	4.9954 mL
	15 mM	0.1332 mL	0.6661 mL	1.3321 mL	3.3303 mL
	20 mM	0.0999 mL	0.4995 mL	0.9991 mL	2.4977 mL
	25 mM	0.0799 mL	0.3996 mL	0.7993 mL	1.9982 mL
	30 mM	0.0666 mL	0.3330 mL	0.6661 mL	1.6651 mL
	40 mM	0.0500 mL	0.2498 mL	0.4995 mL	1.2489 mL
	50 mM	0.0400 mL	0.1998 mL	0.3996 mL	0.9991 mL
	60 mM	0.0333 mL	0.1665 mL	0.3330 mL	0.8326 mL
	80 mM	0.0250 mL	0.1249 mL	0.2498 mL	0.6244 mL

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Keywords

Ranolazine dihydrochloride

5 Cited Publications

100 mg Get Quote

Subscribe to the

MedChemExpress

Newsletter

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

Ranolazine dihydrochloride

Bioactive Compound Library Max

Bioactive Compound Library

Membrane Transporter/Ion Channel Compound Library

Neuronal Signaling Compound Library

FDA-Approved Drug Library

Anti-Cancer Compound Library

Autophagy Compound Library

Drug Repurposing Compound Library

Anti-Cardiovascular Disease Compound Library

Orally Active Compound Library

FDA Approved & Pharmacopeial Drug Library

Neuroprotective Compound Library

Rare Diseases Drug Library

EMA-Approved Drug Library

Calcium Channel Blocker Library

Sodium Channel Blocker Library

FDA-Approved Anticancer Drug Library

Human Metabolite Library

Anti-Prostate Cancer Compound Library

Non-steroidal Anti-Inflammatory Compound Library

Off-patent Drug Library

Antihypertensive Compound Library

Membrane Protein-targeted Compound Library

Membrane Receptor-targeted Compound Library

Cell Death Library

Ion Channel Compound Library

Multi-Target Compound Library

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

High-Throughput Bioactive Compound Library

Mass Spectrometry Human Metabolite Library

Publications Citing Use of MedChemExpress (MCE) Ranolazine dihydrochloride

All Calcium Channel Isoforms

All Sodium Channel Isoforms

Biological Activity

Chemical Information

Publications (5)

Solvent & Solubility

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

Ranolazine dihydrochloride Related Classifications

HY-17401 Related Classifications